929 related articles for article (PubMed ID: 32354228)
1. Clinical Usefulness of PRECISE-DAPT Score for Predicting Bleeding Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An Analysis From the SMART-DATE Randomized Trial.
Choi KH; Song YB; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Gwon HC; Hahn JY
Circ Cardiovasc Interv; 2020 May; 13(5):e008530. PubMed ID: 32354228
[TBL] [Abstract][Full Text] [Related]
2. DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI.
Chichareon P; Modolo R; Kawashima H; Takahashi K; Kogame N; Chang CC; Tomaniak M; Ono M; Walsh S; Suryapranata H; Cotton J; Koning R; Akin I; Kukreja N; Wykrzykowska J; Piek JJ; Garg S; Hamm C; Steg PG; Jüni P; Vranckx P; Valgimigli M; Windecker S; Onuma Y; Serruys PW
JACC Cardiovasc Interv; 2020 Mar; 13(5):634-646. PubMed ID: 32139222
[TBL] [Abstract][Full Text] [Related]
3. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
Hahn JY; Song YB; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Kim J; Choi KH; Park TK; Lee JM; Yang JH; Choi JH; Choi SH; Gwon HC;
Lancet; 2018 Mar; 391(10127):1274-1284. PubMed ID: 29544699
[TBL] [Abstract][Full Text] [Related]
4. Benefits of short-term or prolonged as compared to standard 1 year DAPT in patients with acute coronary syndrome treated with drug-eluting stents: a meta-analysis of 9 randomized trials.
Verdoia M; Kedhi E; Suryapranata H; Frati G; Biondi-Zoccai G; De Luca G
J Thromb Thrombolysis; 2020 Aug; 50(2):337-354. PubMed ID: 31919736
[TBL] [Abstract][Full Text] [Related]
5. Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE) prospective multicenter randomized trial.
Lee JM; Cho DK; Hahn JY; Song YB; Park TK; Oh JH; Lee JB; Doh JH; Kim SH; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC
Am Heart J; 2016 Dec; 182():1-8. PubMed ID: 27914488
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Guideline-Recommended Risk Score-Directed Dual Antiplatelet Therapy After 2nd-Generation Drug-Eluting Stents.
Jang JY; Lee BK; Kim JS; Shin DH; Hong SJ; Ahn CM; Kim BK; Ko YG; Choi D; Hong MK; Park KW; Gwon HC; Kim HS; Kwon HM; Jang Y
Circ J; 2020 Jan; 84(2):161-168. PubMed ID: 31839621
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Outcomes Evaluation After Percutaneous Coronary Intervention in Stable Ischemic Heart Disease and Acute Coronary Syndrome for Short- Versus Standard-Term Dual Antiplatelet Therapy: A Systematic Review and Meta-analysis of Randomized Control Trials.
Bhattarai M; Ibrahim AM; Salih M; Tandan N; Al-Akchar M; Ayan M; Kulkarni A; Hafiz AM
J Cardiovasc Pharmacol; 2020 Nov; 76(5):574-583. PubMed ID: 33165135
[TBL] [Abstract][Full Text] [Related]
8. Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population.
Brener SJ; Kirtane AJ; Rinaldi MJ; Stuckey TD; Witzenbichler B; Weisz G; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Brodie BR; Mehran R; McAndrew T; Stone GW
Circ Cardiovasc Interv; 2018 Oct; 11(10):e006853. PubMed ID: 30354629
[TBL] [Abstract][Full Text] [Related]
9. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.
Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL
Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541
[TBL] [Abstract][Full Text] [Related]
10. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF
Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233
[TBL] [Abstract][Full Text] [Related]
11. One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients.
Kandzari DE; Kirtane AJ; Windecker S; Latib A; Kedhi E; Mehran R; Price MJ; Abizaid A; Simon DI; Worthley SG; Zaman A; Choi JW; Caputo R; Kanitkar M; McLaurin B; Potluri S; Smith T; Spriggs D; Tolleson T; Nazif T; Parke M; Lee LC; Lung TH; Stone GW;
Circ Cardiovasc Interv; 2020 Nov; 13(11):e009565. PubMed ID: 33167705
[TBL] [Abstract][Full Text] [Related]
12. Validating Utility of Dual Antiplatelet Therapy Score in a Large Pooled Cohort From 3 Japanese Percutaneous Coronary Intervention Studies.
Yoshikawa Y; Shiomi H; Watanabe H; Natsuaki M; Kondo H; Tamura T; Nakagawa Y; Morimoto T; Kimura T
Circulation; 2018 Feb; 137(6):551-562. PubMed ID: 28982692
[TBL] [Abstract][Full Text] [Related]
13. Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
Gargiulo G; Ariotti S; Santucci A; Piccolo R; Baldo A; Franzone A; Magnani G; Marino M; Esposito G; Windecker S; Valgimigli M
JACC Cardiovasc Interv; 2016 Sep; 9(17):1780-9. PubMed ID: 27544007
[TBL] [Abstract][Full Text] [Related]
14. An Aspirin-Free Strategy for Immediate Treatment Following Complex Percutaneous Coronary Intervention.
Yamamoto K; Natsuaki M; Watanabe H; Morimoto T; Obayashi Y; Nishikawa R; Ando K; Suwa S; Isawa T; Takenaka H; Ishikawa T; Tamura T; Kawahatsu K; Hayashi F; Akao M; Serikawa T; Mori H; Kawamura T; Hagikura A; Shibata N; Ono K; Kimura T;
JACC Cardiovasc Interv; 2024 May; 17(9):1119-1130. PubMed ID: 38749592
[TBL] [Abstract][Full Text] [Related]
15. Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).
Stefanescu Schmidt AC; Kereiakes DJ; Cutlip DE; Yeh RW; D'Agostino RB; Massaro JM; Hsieh WH; Mauri L;
Circulation; 2017 May; 135(18):1720-1732. PubMed ID: 28228427
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 3- to 6-Month Versus 12-Month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-Eluting Stents With Ultrathin Struts: The HOST-IDEA Randomized Clinical Trial.
Han JK; Hwang D; Yang S; Park SH; Kang J; Yang HM; Park KW; Kang HJ; Koo BK; Hur SH; Kim W; Kim SY; Park SH; Han SH; Kim SH; Shin S; Kim YH; Park K; Lee N; Lee SJ; Kim JW; Kim HS
Circulation; 2023 May; 147(18):1358-1368. PubMed ID: 36871230
[TBL] [Abstract][Full Text] [Related]
17. Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical Presentation.
Palmerini T; Bruno AG; Gilard M; Morice MC; Valgimigli M; Montalescot G; Collet JP; Della Riva D; Bacchi-Reggiani ML; Steg PG; Diallo A; Vicaut E; Helft G; Nakamura M; Généreux P; Vahl TP; Stone GW
Circ Cardiovasc Interv; 2019 Mar; 12(3):e007541. PubMed ID: 30871353
[TBL] [Abstract][Full Text] [Related]
18. Validation of contemporary risk scores in predicting coronary thrombotic events and major bleeding in patients with acute coronary syndrome after drug-eluting stent implantations.
Song L; Guan C; Yan H; Qiao S; Wu Y; Yuan J; Dou K; Yang Y; Dangas GD; Xu B
Catheter Cardiovasc Interv; 2018 Feb; 91(S1):573-581. PubMed ID: 29322612
[TBL] [Abstract][Full Text] [Related]
19. One- versus three-month dual antiplatelet therapy in high bleeding risk patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromes.
Cao D; Vranckx P; Valgimigli M; Sartori S; Angiolillo DJ; Bangalore S; Bhatt DL; Feng Y; Ge J; Hermiller J; Makkar RR; Neumann FJ; Saito S; Picon H; Toelg R; Maksoud A; Chehab BM; Choi JW; Campo G; De la Torre Hernandez JM; Krucoff MW; Kunadian V; Sardella G; Spirito A; Thiele H; Varenne O; Vogel B; Zhou Y; Windecker S; Mehran R
EuroIntervention; 2024 May; 20(10):e630-e642. PubMed ID: 38776146
[TBL] [Abstract][Full Text] [Related]
20. Benefit of Prolonged Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stent for Coronary Bifurcation Lesions: Results From the Coronary Bifurcation Stenting Registry II.
Jang WJ; Ahn SG; Song YB; Choi SH; Chun WJ; Oh JH; Cho SW; Kim BS; Yoon JH; Koo BK; Yu CW; Jang YS; Tahk SJ; Kim HS; Gwon HC; Lee SY; Hahn JY
Circ Cardiovasc Interv; 2018 Jul; 11(7):e005849. PubMed ID: 30006330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
